Reuters logo
BRIEF-Cara receives breakthrough therapy designation from FDA for I.V. CR845
June 23, 2017 / 11:13 AM / 3 months ago

BRIEF-Cara receives breakthrough therapy designation from FDA for I.V. CR845

June 23 (Reuters) - Cara Therapeutics Inc:

* Cara receives breakthrough therapy designation from FDA for I.V. CR845 for the treatment of chronic kidney disease-associated pruritus in hemodialysis patients Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below